Table of contents
Volume 91, Issue 8
Published online 12 October 2004 (1415-1631)
Clinical |
Molecular and Cellular Pathology |
Genetics and Genomics |
Experimental Therapeutics
Minireviews
Targeting the p53–MDM2 interaction to treat cancer FREE
C Klein and L T Vassilev
Br J Cancer 91: 1415-1419; advance online publication, September 28, 2004; doi:10.1038/sj.bjc.6602164
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer FREE
S Chan
Br J Cancer 91: 1420-1424; advance online publication, September 14, 2004; doi:10.1038/sj.bjc.6602162
Clinical
Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer FREE
T M Beer, M Garzotto, W D Henner, K M Eilers and E M Wersinger
Br J Cancer 91: 1425-1427; advance online publication, October 5, 2004; doi:10.1038/sj.bjc.6602198
Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil FREE
A Guglielmi, S Barni, A Zaniboni, N Pella, O Belvedere, G D Beretta, F Grossi, L Frontini, F Puglisi, R Labianca and A Sobrero on behalf of the Gruppo Italiano Studio Carcinomi Apparato Digerente (GISCAD)
Br J Cancer 91: 1428-1433; advance online publication, September 21, 2004; doi:10.1038/sj.bjc.6602176
A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer FREE
N E Schoemaker, I E L M Kuppens, V Moiseyenko, B Glimelius, M Kjaer, H Starkhammer, D J Richel, R Smaaland, K Bertelsen, J P Poulsen, E Voznyi, J Norum, D Fennelly, K M Tveit, A Garin, G Gruia, A Mourier, D Sibaud, P Lefebvre, J H Beijnen, J H M Schellens and W W ten Bokkel Huinink
Br J Cancer 91: 1434-1441; advance online publication, September 21, 2004; doi:10.1038/sj.bjc.6602172
Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX FREE
F Recchia, G Saggio, A Nuzzo, A Lalli, L Di Lullo, A Cesta and S Rea
Br J Cancer 91: 1442-1446; advance online publication, October 5, 2004; doi:10.1038/sj.bjc.6602194
Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer FREE
M P Saunders, M Hogg, B Carrington, A-M Sjursen, J Allen, J Beech, R Swindell and J W Valle
Br J Cancer 91: 1447-1452; advance online publication, September 28, 2004; doi:10.1038/sj.bjc.6602173
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy FREE
I Chau, A R Norman, D Cunningham, J S Waters, C Topham, G Middleton, M Hill, P J Ross, R Katopodis, G Stewart and J R Oates
Br J Cancer 91: 1453-1458; advance online publication, September 14, 2004; doi:10.1038/sj.bjc.6602169
Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1–5 of a 3-weekly cycle in patients with advanced solid tumours FREE
M J A de Jonge, S Kaye, J Verweij, C Brock, S Reade, M Scurr, L van Doorn, C Verheij, W Loos, C Brindley, P Mistry, M Cooper and I Judson
Br J Cancer 91: 1459-1465; advance online publication, September 28, 2004; doi:10.1038/sj.bjc.6602178
Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer FREE
J Bonneterre, V Dieras, M Tubiana-Hulin, P Bougnoux, M-E Bonneterre, T Delozier, F Mayer, S Culine, N Dohoulou and B Bendahmane
Br J Cancer 91: 1466-1471; advance online publication, September 21, 2004; doi:10.1038/sj.bjc.6602179
Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer FREE
A J Birtle, J C Newby and S J Harland
Br J Cancer 91: 1472-1476; advance online publication, September 21, 2004; doi:10.1038/sj.bjc.6602177
Effect of process standards on survival of patients with head and neck cancer in the south and west of England FREE
M Birchall, D Bailey and P King on behalf of the South West Cancer Intelligence Service Head and Neck Tumour Panel
Br J Cancer 91: 1477-1481; advance online publication, October 5, 2004; doi:10.1038/sj.bjc.6602118
Breast cancer: patient information needs reflected in English and German web sites FREE
C Weissenberger, S Jonassen, J Beranek-Chiu, M Neumann, D Müller, S Bartelt, S Schulz, J S Mönting, K Henne, G Gitsch and G Witucki
Br J Cancer 91: 1482-1487; advance online publication, October 5, 2004; doi:10.1038/sj.bjc.6602168
Molecular and Cellular Pathology
Activation of p53 by scaffold-stabilised expression of Mdm2-binding peptides: visualisation of reporter gene induction at the single-cell level FREE
G B Karlsson, A Jensen, L F Stevenson, Y L Woods, D P Lane and M S Sørensen
Br J Cancer 91: 1488-1494; advance online publication, September 21, 2004; doi:10.1038/sj.bjc.6602143
Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma FREE
C S Vetter, W Lieb, E-B Bröcker and J C Becker
Br J Cancer 91: 1495-1499; advance online publication, September 21, 2004; doi:10.1038/sj.bjc.6602123
Antibodies to CD20 and MHC class II antigen bound to B-lymphoma cells accumulate in shed cytoplasmic fragments FREE
R B Michel and M J Mattes
Br J Cancer 91: 1500-1507; advance online publication, September 28, 2004; doi:10.1038/sj.bjc.6602131
Pyridoxal phosphatase is a novel cancer autoantigen in the central nervous system FREE
A S Bøe, G Bredholt, P M Knappskog, A Storstein, C A Vedeler and E S Husebye
Br J Cancer 91: 1508-1514; advance online publication, September 28, 2004; doi:10.1038/sj.bjc.6602142
S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas FREE
S L Smith, M Gugger, P Hoban, D Ratschiller, S G Watson, J K Field, D C Betticher and J Heighway
Br J Cancer 91: 1515-1524; advance online publication, October 5, 2004; doi:10.1038/sj.bjc.6602188
The effect of cigarette smoking use and cessation on serum insulin-like growth factors FREE
A G Renehan, W S Atkin, S T O'Dwyer and S M Shalet
Br J Cancer 91: 1525-1531; advance online publication, August 31, 2004; doi:10.1038/sj.bjc.6602150
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma FREE
D M Abd El-Rehim, S E Pinder, C E Paish, J A Bell, R S Rampaul, R W Blamey, J F R Robertson, R I Nicholson and I O Ellis
Br J Cancer 91: 1532-1542; doi:10.1038/sj.bjc.6602184
Differential gene expression profiles of radioresistant oesophageal cancer cell lines established by continuous fractionated irradiation FREE
K Fukuda, C Sakakura, K Miyagawa, Y Kuriu, S Kin, Y Nakase, A Hagiwara, S Mitsufuji, Y Okazaki, Y Hayashizaki and H Yamagishi
Br J Cancer 91: 1543-1550; advance online publication, September 14, 2004; doi:10.1038/sj.bjc.6602187
Polymorphism in heme oxygenase-1 (HO-1) promoter is related to the risk of oral squamous cell carcinoma occurring on male areca chewers FREE
K-W Chang, T-C Lee, W-I Yeh, M-Y Chung, C-J Liu, L-Y Chi and S-C Lin
Br J Cancer 91: 1551-1555; advance online publication, September 14, 2004; doi:10.1038/sj.bjc.6602186
An immunohistochemical study of TIMP-3 expression in oesophageal squamous cell carcinoma FREE
T Miyazaki, H Kato, M Nakajima, A Faried, J Takita, M Sohda, Y Fukai, S Yamaguchi, N Masuda, R Manda, M Fukuchi, H Ojima, K Tsukada and H Kuwano
Br J Cancer 91: 1556-1560; advance online publication, October 5, 2004; doi:10.1038/sj.bjc.6602185
Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines FREE
Y-C Shen, C Hsu, J-Y Chen and A-L Cheng
Br J Cancer 91: 1561-1565; advance online publication, October 5, 2004; doi:10.1038/sj.bjc.6602200
Zinc-finger protein ZNF165 is a novel cancer-testis antigen capable of eliciting antibody response in hepatocellular carcinoma patients FREE
X-Y Dong, X-A Yang, Y-D Wang and W-F Chen
Br J Cancer 91: 1566-1570; advance online publication, August 31, 2004; doi:10.1038/sj.bjc.6602138
Genetics and Genomics
Development of spontaneous tumours and intestinal lesions in Fhit gene knockout mice FREE
T Fujishita, Y Doi, M Sonoshita, H Hiai, M Oshima, K Huebner, C M Croce and M M Taketo
Br J Cancer 91: 1571-1574; advance online publication, October 5, 2004; doi:10.1038/sj.bjc.6602182
A cross-sectional survey to estimate the prevalence of family history of colorectal, breast and ovarian cancer in a Scottish general practice population FREE
E Wallace, A Hinds, H Campbell, J Mackay, R Cetnarskyj and M E M Porteous
Br J Cancer 91: 1575-1579; advance online publication, September 21, 2004; doi:10.1038/sj.bjc.6602155
The BOADICEA model of genetic susceptibility to breast and ovarian cancer FREE
A C Antoniou, P P D Pharoah, P Smith and D F Easton
Br J Cancer 91: 1580-1590; advance online publication, September 21, 2004; doi:10.1038/sj.bjc.6602175
Expression of the transcription factor CTCF in invasive breast cancer: a candidate gene located at 16q22.1 FREE
E A Rakha, S E Pinder, C E Paish and I O Ellis
Br J Cancer 91: 1591-1596; advance online publication, August 31, 2004; doi:10.1038/sj.bjc.6602144
Sp17 gene expression in myeloma cells is regulated by promoter methylation FREE
Z Wang, Y Zhang, B Ramsahoye, D Bowen and S H Lim
Br J Cancer 91: 1597-1603; advance online publication, September 21, 2004; doi:10.1038/sj.bjc.6602160
Genetic variation in XRCC1, sun exposure, and risk of skin cancer FREE
J Han, S E Hankinson, G A Colditz and D J Hunter
Br J Cancer 91: 1604-1609; advance online publication, September 21, 2004; doi:10.1038/sj.bjc.6602174
Experimental Therapeutics
Impaired neutralising antibody formation and high transduction efficacy after isolated hepatic perfusion with adenoviral vectors FREE
B van Etten, A M M Eggermont, G Ambagtsheer, S T van Tiel and T L M ten Hagen
Br J Cancer 91: 1610-1613; doi:10.1038/sj.bjc.6602151
Characterisation of molecular events following cisplatin treatment of two curable ovarian cancer models: contrasting role for p53 induction and apoptosis in vivo FREE
P A Clarke, K E Pestell, F Di Stefano, P Workman and M I Walton
Br J Cancer 91: 1614-1623; advance online publication, September 28, 2004; doi:10.1038/sj.bjc.6602167
Dietary induction of NQO1 increases the antitumour activity of mitomycin C in human colon tumours in vivo FREE
A Begleiter, M K Leith, J A Thliveris and T Digby
Br J Cancer 91: 1624-1631; advance online publication, October 5, 2004; doi:10.1038/sj.bjc.6602171
The published online date indicates the date that the issue is published online and is the first official publication date of the issue. Each print issue of BJC is published one week after it has been published online.
